Q2 2026 Lantern Pharma Inc Earnings Call Transcript
Key Points
- Lantern Pharma Inc (LTRN) reported a 25% reduction in total operating expenses year-over-year, demonstrating disciplined financial management.
- The company's lead drug candidate, LP-300, showed promising clinical data in the HARMONIC trial, with a median progression-free survival of 8.9 months in L858R patients who completed six cycles and a hazard ratio of 0.37.
- Lantern Pharma Inc (LTRN) received EMA clearance for a Phase Ib/II trial of LP-184 in advanced bladder cancer and FDA clearance for a Phase Ib/II trial in triple-negative breast cancer, expanding its clinical pipeline.
- The company established Open Medicine AI (OMAI) as a separate entity, which is 100% owned by Lantern Pharma Inc (LTRN) and aims to commercialize its AI platform, potentially unlocking significant value for shareholders.
- Lantern Pharma Inc (LTRN) received a notice of allowance for a patent covering a three-gene patient selection method for LP-184, strengthening its intellectual property portfolio.
- The company's AI-driven approach has advanced three drug candidates to clinical trials in under three years at a fraction of the industry cost, highlighting operational efficiency.
- Lantern Pharma Inc (LTRN) reported a net loss of $7.1 million for Q2 2026, which was higher than the $4.3 million loss in Q2 2025, primarily due to noncash warrant expenses.
- The company's cash position decreased to $7.4 million as of June 30, 2026, from $10.1 million at the end of 2025, indicating a need for additional capital to fund operations.
- The clinical data for LP-300 is based on small exploratory cohorts (e.g., nine patients), which are not powered for statistical significance and could change as more data is collected.
- Lantern Pharma Inc (LTRN) faces significant competition in the AI-driven drug discovery space, with larger companies having more capital and resources.
- The company's ability to generate revenue from its AI platform, Open Medicine AI, is unproven, and the market for such tools is still emerging, posing execution risks.
- The company's stock price volatility, driven by warrant accounting, could create uncertainty for investors, as seen in the $3.6 million noncash expense recorded in Q2 2026.
Good morning and welcome to our second quarter 2026 earnings call. As a reminder, this call is being recorded, (Operator Instructions) A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call.
We issued a press release before market opened today, summarizing our financial results and progress across the company for the second quarter ended June 30, 2026. A copy of this release is available through our website at lanternpharma.com where you will also find a link to the slides management will be referencing on today's call.
We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
